Artelo Biosciences, Inc. - Common Stock (ARTL)
Frequently Asked Questions About Artelo Biosciences, Inc. - Common Stock (ARTL)
How can investors track Artelo's performance?
Investors can track Artelo's performance by monitoring its stock price on the Nasdaq under the ticker ARTL, reviewing quarterly financial reports, and following news releases that provide updates on clinical trial results, partnerships, and other significant milestones.
How does Artelo approach cannabinoid research?
Artelo approaches cannabinoid research by focusing on the pharmacology of cannabinoid compounds, their interactions with the human body, and how these interactions can be optimized to create effective therapies. The company employs rigorous scientific methods to validate its hypotheses and bring promising candidates to clinical trials.
How does Artelo define success?
Artelo defines success by the ability to develop and commercialize effective therapies that improve patients' lives, achieve regulatory approvals, and create value for shareholders. The company also considers successful partnerships and advancements in its clinical programs as key indicators of its growth.
How does Artelo fund its operations?
Artelo funds its operations through a combination of public and private investment, including offerings of its common stock. The company also seeks grant funding and strategic partnerships to support its research initiatives and clinical trials.
Is Artelo Biosciences, Inc. publicly traded?
Yes, Artelo Biosciences, Inc. is publicly traded on the Nasdaq under the ticker symbol ARTL. The company went public to raise capital to support its research and development efforts.
What are Artelo's long-term goals?
Artelo's long-term goals include successfully bringing its drug candidates through clinical trials to commercialization, expanding its therapeutic pipeline, and ultimately providing patients with innovative treatments that improve their quality of life.
What are the company's recent achievements?
Artelo has made several recent achievements, including advancements in clinical trial phases for its lead drug candidates, successful fundraising efforts, and collaborations with research institutions to enhance its drug development capabilities.
What are the key products in Artelo's pipeline?
Artelo's pipeline includes several key products such as ART27.13, a proprietary formulation of cannabinoids being evaluated for its potential in treating cancer and related symptoms, and other cannabinoid-based treatments aimed at addressing serious medical conditions.
What challenges does Artelo face?
Some challenges Artelo faces include navigating the complex regulatory landscape governing biotechnology products, securing funding for its research and development activities, and demonstrating the clinical efficacy of its therapies in competitive therapeutic areas.
What does Artelo Biosciences, Inc. do?
Artelo Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for patients suffering from a range of diseases, including cancer and other serious medical conditions. The company utilizes its proprietary cannabinoid and other therapeutic platforms to advance its drug candidates through clinical trials with the aim of addressing unmet medical needs.
What is Artelo's mission?
Artelo's mission is to improve the quality of life for patients through the development of innovative and effective therapies that harness the potential of cannabinoids. The company strives to bring new treatments to market that address significant unmet medical needs.
What is Artelo's primary focus?
Artelo's primary focus is on the development of novel therapeutics that harness the properties of cannabinoids to enhance treatment outcomes in patients with chronic and complex diseases, particularly cancer and metabolic disorders.
What is the significance of the ticker symbol ARTL?
The ticker symbol ARTL represents Artelo Biosciences, Inc. on the Nasdaq stock exchange. Ticker symbols are unique identifiers for publicly traded companies, making it easier for investors to track the performance of specific stocks.
What kind of investor relations does Artelo provide?
Artelo provides investor relations through regular communication, including press releases, financial reports, and conference calls. The company aims to keep its investors informed about its financial performance, strategic initiatives, and progress in drug development.
What partnerships does Artelo have?
Artelo Biosciences has established strategic partnerships with various academic institutions and research organizations to foster innovation and facilitate clinical research. These collaborations aim to enhance the company's drug development initiatives and expedite the progress of its pipeline.
What regulatory approvals does Artelo require?
Artelo must obtain regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) before its drug candidates can proceed from clinical trials to market. These approvals involve a rigorous review process that evaluates the safety and efficacy of the proposed treatments.
When was Artelo Biosciences, Inc. founded?
Artelo Biosciences, Inc. was founded in 2015. Since its inception, the company has been dedicated to the research and development of cannabinoid-based therapies aiming to leverage the therapeutic potential of cannabinoids in treating various diseases.
Where is Artelo Biosciences, Inc. headquartered?
Artelo Biosciences, Inc. is headquartered in San Diego, California. This location positions the company within a vibrant biotechnology hub, facilitating collaborations and access to resources in the biotech industry.
Who are the key executives at Artelo Biosciences, Inc.?
The key executives at Artelo Biosciences include experienced professionals from the biotechnology and pharmaceutical industries. Leadership includes individuals with a proven track record in drug development, regulatory affairs, and business operations, driving the company's strategic vision forward.
What is the current price of Artelo Biosciences, Inc. - Common Stock?
The current price of Artelo Biosciences, Inc. - Common Stock is 10.05
When was Artelo Biosciences, Inc. - Common Stock last traded?
The last trade of Artelo Biosciences, Inc. - Common Stock was at 1:00 pm EDT on July 3rd, 2025
What is the market capitalization of Artelo Biosciences, Inc. - Common Stock?
The market capitalization of Artelo Biosciences, Inc. - Common Stock is 32.97M
How many shares of Artelo Biosciences, Inc. - Common Stock are outstanding?
Artelo Biosciences, Inc. - Common Stock has 3.28M shares outstanding.